Nexus Pharmaceuticals Inc., an Illinois-based healthcare company, has announced that it has received Food and Drug Administration (FDA) approval for generic Erythrocin (erythromycin lactobionate) injection in 500mg/vial in single-dose vials, according to Business Wire.
Usman Ahmed, Chief Operating Officer at Nexus, said, “We are very proud of the hard work of our team in gaining approval of this product. Bringing this product to market showcases Nexus’ commitment to ending drug shortages in the US and solving today’s critical healthcare challenges.”
Nexus’ generic erythromycin lactobionate for injection will be available in cartons of five single-dose vials.
Originally developed by Pfizer, Erythrocin Lactobionate intravenous is indicated in the treatment of infections suspected to be caused by bacteria strains.
The drug is advised oral erythromycin administration is not possible. It is also recommended when the severity of the bacterial infection requires high serum levels of erythromycin.
Erythrocin Lactobionate Injection is used to treat upper respiratory tract infections, lower respiratory tract infections, bacterial skin or skin structure infections, diphtheria, erythrasma, acute pelvic inflammatory disease, gonorrhea, syphilis, Legionnaires’ disease, bacterial endocarditis, among others. It is also used as a prophylaxis treatment for certain bacterial infections.
Nexus is a certified diverse drug supplier that specializes in innovative processes to make difficult-to-manufacture specialty and generic drugs.
The company ensures that its FDA-approved drugs are high in quality so they can fulfill a critical unmet medical need and deliver dependable life-saving treatment options.
Nexus is not the only pharmaceutical company to receive FDA approval for generic erythromycin lactobionate injection.
In September 2020, Exela Pharma Sciences LLC, a North Carolina-based specialty pharmaceutical company, received approval for generic erythromycin lactobionate injectable in 500mg/vial.
Brand Erythrocin first received FDA approval in 1982. Hospira received the FDA approval. However, Hospira is now part of Pfizer.
